Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveCME Group Maintained at Neutral by UBS

Live News EQUITY FLASH L impact Oct 05, 2026, 09:06 PM UTC

CME Group Maintained at Neutral by UBS

UBS maintained its Neutral rating on CME Group.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

CME

Related stories

Canada Invests Toward Rio Tinto’s Quebec Aluminum Modernization Projects Innovation, Science and Economic Development Canada is investing toward Rio Tinto’s aluminum modernization projects in Quebec. L impact | EQUITY | Oct 23, 2026, 04:39 PM UTC Genmab Says Rinatabart Sesutecan Improves Progression-Free Survival M impact | EQUITY | Oct 23, 2026, 04:38 PM UTC Infosys Reports $5.2 Billion in Q2 FY27 Large Deal Wins Infosys said large deals had total contract value of $5.2 billion in Q2 FY27. The wins included a mega deal valued at more than $2 billion, compared with $3.6 billion in large deal M impact | EQUITY | Oct 23, 2026, 04:37 PM UTC BPCL Q2 Net Profit Falls 22% to ₹4,863 Crore Bharat Petroleum reported consolidated net profit of around ₹4,863 crore in Q2 FY27, down almost 22% year on year. Higher refinery margins were offset by losses from petrol, diesel M impact | EQUITY | Oct 23, 2026, 04:37 PM UTC CSB Bank Q2 Net Profit Rises 14% to ₹182.72 Crore Standalone net profit was ₹182.72 crore in the quarter ended September 30, 2026, compared with ₹160.33 crore a year earlier. The bank cited better net interest income and lower pro M impact | EQUITY | Oct 23, 2026, 04:36 PM UTC Tango Therapeutics Shares Fall 14% After Pancreatic Cancer Study Results An ongoing study found vopimetostat was not well tolerated at a certain dose level. Tango Therapeutics shares fell 14% to $24.13 on Friday. M impact | EQUITY | Oct 23, 2026, 04:36 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.